Oruka Therapeutics (ORKA) Non-Current Assets (2010 - 2026)

Oruka Therapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $109.2 million for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 336.42% year-over-year to $109.2 million in Q1 2026; TTM through Mar 2026 was $433.5 million, a 855.99% increase from a year earlier, with the FY2025 full-year figure at $144.8 million, up 655.93% from the prior year.
• Non-Current Assets slipped to $109.2 million in Q1 2026 per ORKA's latest filing, from $144.8 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $154.1 million in Q3 2025 and bottomed at $24000.0 in Q2 2024.
• The 5-year median for Non-Current Assets is $446000.0 (2022), against an average of $28.3 million.
• Across the five-year window, Non-Current Assets plunged 92.68% in 2024 and surged 105758.33% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $386000.0 in 2022, then tumbled by 30.31% to $269000.0 in 2023, then jumped by 7018.96% to $19.2 million in 2024, then jumped by 655.93% to $144.8 million in 2025, then declined by 24.54% to $109.2 million in 2026.
• Per Business Quant, the three latest ORKA Non-Current Assets figures stand at $109.2 million (Q1 2026), $144.8 million (Q4 2025), and $154.1 million (Q3 2025).